bioRxivImmunologyPreprint
Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: A new tumour stromal cell immune checkpoint?
H. Egan, O. Treacy, K. Lynch, N. A. Leonard, G. O'Malley, K. DeVeirman, K. Vanderkerken, M. Craughwell, L. J. Egan, T. Ritter, A. M. Hogan, K. Redmond, M. Sheehan, A. Canney, S. Hynes, E. M. Kerr, P. D. Dunne, M. E. O'Dwyer, A. E. Ryan
Abstract
Immunosuppressive tumour microenvironments (TME) reduce the effectiveness of immune responses in cancer. Non-haematopoietic mesenchymal stromal cells (MSC), the precursor to cancer associated fibroblasts (CAFs), dictate tumour progression by enhancing immune cell suppression. Hyper-sialylation of glycans promotes immune evasion in cancer, but the role of sialyation in stromal cell-mediated immunosuppression is unknown. Here we study changes in sialyltransferase (ST) enzymes and associated surface expressed sialic acid in stromal cells following inflammatory and tumour secretome conditioning. We show that tumour conditioned stromal cells have increased levels of sialyltransferases, 2,3/6 linked sialic acid and siglec ligands. In tumour models of solid (colorectal cancer) and haematological (multiple myeloma) stromal rich tumours, stromal cell sialylation is associated with enhanced immunosuppression. Using datasets and patient samples, we confirm that targeting sialylation in tumour stromal cells reverses immune cell exhaustion. Targeting stromal cell sialylation may represent a novel immune checkpoint to reactivate anti-tumour immunity.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axis
Aoise O’Neill, Norashikin Zakaria, … Aideen E. Ryan·Journal for ImmunoTherapy of CancerPeer-reviewed·Oct 1, 2025
- Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2
R. Wieboldt, E. Carlini, … N. Rodrigues Mantuano·bioRxiv·Jun 29, 2023
- Tumor sialylation controls effective anti-cancer immunity in breast cancer
S. Mereiter, G. Jonsson, … J. M. Penninger·bioRxiv·Sep 20, 2023
- Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
M. A. Stanczak, N. R. Mantuano, … H. Laeubli·Science Translational MedicinePeer-reviewed·Nov 2, 2022
- Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a mechanism involving membrane-bound TGF-β1.
Thomas Boyer, Céline Blaye, … Nicolas Larmonier·bioRxiv·Feb 21, 2025
- Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1